ABSTRACT-The intravascular application of radiographic contrast media causes hypersensitivity reac tions, in which histamine release may play a major role. We examined the interaction between contrast medium and morphine. Among the four nonionic contrast media examined, iopamidol showed the most marked histamine release from rat peritoneal mast cells in vitro. Although iopamidol and morphine them selves did not induce histamine release at concentrations up to 65 mgI/ml and 3 mM, respectively, their combination resulted in a significant histamine release. These findings suggest that patients with exposure to medicines that induce histamine release may have a higher incidence and severity of hypersensitivity reac tions to radiographic contrast media.
Iodinated radiographic
contrast media (RCM) are widely used for image enhancement in several diagnostic procedures. However, many undesirable adverse reac tions to RCM including allergic, renal, vascular and cardiac effects have been reported (1) . Even the nonionic RCM with lower osmolarity induce these reactions, although the incidence has been reported to be reduced as compared with ionic RCM (2) .
Non-immunologic anaphylactoid reactions are also commonly associated with RCM infusion procedures (1) . Anaphylactoid reactions are unpredictable and dose-in dependent and may manifest as bronchospasm, airway edema, gastrointestinal distress, urticaria and angio edema. The pathogenic mechanism of anaphylactoid reac tions observed during RCM infusion is still unclear. The results of in vitro and in vivo studies suggest that hista mine release from basophils and/or mast cells plays a major role in these reactions (3, 4) . Several pretreatment regimens including H1 and H2-antagonists for the prophylaxis of anaphylactoid reactions to RCM have been studied (5) . Some risk factors for anaphylactoid reactions have been reported such as personal history of allergy/atopy, cardiovascular diseases and previous reactions to RCM (6, 7) . However, there has been no report regarding the interaction with other medicines possessing the *To whom correspondence should be addressed .
histamine-releasing effect. If RCM are administered to patients taking such medicines, the incidence and severity of anaphylactoid reactions might increase. In this study, we examined the interaction between RCM and morphine in the histamine release from rat peritoneal mast cells, because morphine is widely used, especially for the relief of cancer pain, and is also known to have histamine releasing action (8, 9) . Male Sprague-Dawley rats (Kyushu University Institute of Laboratory Animals), weighing 300-350g, were anesthetized with ether and exsanguinated by cutting one of the carotid arteries. Then, 20 ml of ice-cold Hanks' balanced salt solution (HBSS; 137 mM NaC1, 5.36 mM KCI, 0.20 mM MgSO4i 0.34 mM Na2HPO4, 0.44 mM KH2PO4, 4.17 mM NaHCO3, 1.26 mM CaC12 and 5.6 mM glucose) was injected into the peritoneal cavity. After gentle massage of the abdomen for 90 sec, the intra peritoneal fluid was collected with a plastic pipette. Usually the cells collected from 2-4 rats were pooled and used for one set of experiments. The mast cells were separated from the peritoneal fluid by centrifugation at 125 x g for 5 min at 41C, washed twice with HBSS and then finally resuspended in HBSS.
Various concentrations of RCM diluted with distilled water and morphine dissolved in HBSS were prepared. Each aliquot of the mast cells (1 x 104) suspension in HBSS was preincubated at 37°C for 5 min. RCM (1.0 ml) alone or in combination with various concentrations of morphine (0.1 ml) were added to the cell suspensions (0.5 and 0.4 ml, respectively) and incubated for another 5 min at 37C. The reaction was terminated by placing the test tubes in crushed ice. After centrifugation (125 x g, 5 min, 41C), the upper 0.75 ml of the supernatant was carefully transferred to another plastic tube, and 15 ul of 5.1 N perchloric acid was added. To the lower fraction, 0.75 ml of HBSS and 30 ul of 5.1 N perchloric acid were added, and the mixture was then ultrasonicated. The histamine contents of both fractions were determined with ion-pair HPLC coupled with postcolumn fluorescent derivatiza tion (10) . None of the drugs used in the present study interfered with the fluorometric assay. The extent of the histamine release (histamine in the supernatant) from the mast cells is expressed as the percentage of the total histamine content (intracellular + supernatant hista mine). First, we examined the histamine releasing effects of four nonionic RCM in rat peritoneal mast cells. The spontaneous histamine release determined in HBSS without RCM was 5.7±0.5% (Fig. 1) . Among the RCM examined, iopamidol showed the greatest histamine re lease at 135 mgI/ml (20.3±0.5%). lomeprol and ioversol also showed significant histamine release at the same con centration (9.2±0.2 and 10.5-L0.7%, respectively). At 200 mgI/ml, these three RCM showed significant hista mine releases, but to extents almost the same as those at 135 mgI/ml. The iohexol-induced histamine release was not significantly different from spontaneous histamine release, although the extent was similar to those by iomeprol and ioversol. Figure 2 shows the interaction between morphine and iopamidol (the most potent histamine releaser of the four RCM in the first experiment) in the histamine release from rat peritoneal mast cells. Morphine itself did not induce histamine release at concentrations up to 3 mM, but synergistically enhanced histamine release induced by iopamidol over the concentration range tested. The non-significant histamine release induced by iopamidol at 20 mgI/ml (9.7±0.4%) was clearly increased to 15.6±1.3%, 47.7±2.4% and 81.4±2.4% by the combi nation with 1 mM, 3 mM and 10 mM of morphine, respectively.
Since hyperosmolarity may be responsible for some of the adverse reactions caused by RCM (11, 12) , new RCM with lower osmolarity have been developed. With the use of these novel preparations, the incidence of overall ad verse reactions was reduced from 12.66% of patients who received higher osmolar RCM to 3.31 %, and the inci dence of severe anaphylactoid reactions (sudden drop in blood pressure, cardiac arrest, loss of consciousness, or dyspnea requiring treatment) was reduced from 0.22% to 0.04% (2) .
Similar to the incidence of anaphylactoid reactions, histamine releases induced by lower osmolar RCM have been reported to be lower than those induced by hyperosmolar RCM (13) . In the present study, we used nonionic RCM with lower osmolarity. Histamine re leases from rat peritoneal mast cells ranged from 9.2% to 20.3% at the concentration of 135 mgI/ml. These values are similar to those reported previously (13) . Some risk factors for anaphylactoid reactions to RCM have been found (6, 7) . As for the medicines, Lang et al. (14) reported that patients receiving beta-blockers had a sig nificantly higher risk of anaphylactoid reactions, prob ably due to reduced beta-adrenergic responsiveness.
The present results are the first evidence of the positive interaction of histamine release by RCM with other medicines in vitro. Iopamidol-induced histamine release was synergistically enhanced by the addition of mor phine. Even at concentrations at which iopamidol and morphine themselves induce no histamine release, the combination (e.g., 65 mgI/m1 of iopamidol and 1 mM of morphine) resulted in significant histamine release. Non specific histamine release from mast cells by various therapeutic drugs in high doses may occur by a rise in intracellular Ca t+, but the detailed mechanism is still unknown (15) . The positive interaction of histamine re lease by RCM with morphine might have been due to a decrease in the threshold for a rise in intracellular Cat+.
In the experimental system used, a considerably high concentration of morphine was required to induce hista mine release. However, this is in good agreement with the previous report (8) , and the histamine releasing action of morphine was observed in patients (9) . These findings suggest that patients with exposure to medicines that induce histamine release may have a higher incidence and greater severity of anaphylactoid reactions to RCM. Great caution should be taken in the use of RCM in patients receiving such medicines. 
